Skip to main content
. 2020 Dec 19;8(4):778. doi: 10.3390/vaccines8040778

Table 1.

Demographic characteristics and SARS-CoV-2 seroprevalence of the study population.

Type of Service N
(% of the whole sample)
N of Males (% within the Group) * Median Age, Years (IQR) # N of Positive Participants (% of within the Group) * % Positive Participants 95% CI
Work-from-home 725 (15.6%) 248 (34.2%) 49.0 (39.7–56.0) 7 (1.0%) 0.3%–2.0%
Support Service (total) 1103 (23.7%) 481 (43.6%) 50.0 (36.0–61.0) 15 (1.4%) 0.7%–2.2%
Community support service 502 (10.8%) 327 (65.1%) 53.3 (34.3–64.5) 5 (1.0%) 0.3%–2.3%
Local health authority support service 601 (12.9%) 154 (25.6%) 48.0 (37–59.0) 10 (1.7%) 0.8–3.0%
Health Service 2828 (60.7%) 803 (28.4%) 48.0 (38.0–56.0) 116 (4.1%) 3.4%–4.9%
Total sample 4656 (100%) 1532 (32.9%) 49.0 (38.0–57.0) 138 (3.0%) 2.5%–3.5%

* p < 0.01 Chi2 Test; # p < 0.01 Kruskal–Wallis test.